Mercado Donar ahora Conviértase en Miembro

Carrito (0)

Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Eventos globales

Bethesda North Marriott Hotel and Conference Center

25 oct 2017 7:00 a.m. - 27 oct 2017 3:00 p.m.

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Convening industry and health authorities to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

Volver a Agenda

Session 1: The Emerging Landscape of mRNA-Based Drugs: A New Modality in Vaccines and Therapeutics

Session Chair(s)

Tal Zaks, MD, PHD

Tal Zaks, MD, PHD

Venture Partner, OrbiMed, United States

mRNA therapeutics are unique, relative to most oligonucleotide-based modalities like antisense, siRNAs, and aptapers in that mRNAs enable expression of the encoded protein rather than act as antagonists to inhibit target protein translation or activity. Early clinical data indicate that mRNA-based drugs may be effective vaccines and their potential as therapeutics is now emerging. This session will describe the general approach to mRNA manufacture, present emerging preclinical and clinical data on mRNA vaccines and therapeutics, and provide a regulatory perspective on the product-related (CMC) aspects of mRNA drug development.

Learning Objective :
Analyze the general approach to CMC regulation of mRNA drugs and differentiate relative to synthetic oligonucleotides
Describe the current development status of mRNA vaccines and therapeutics

Speaker(s)

Session Co-Chair

Primary Reviewer, Regulatory Project Manager, OVRR, CBER, FDA, United States

Tal Zaks, MD, PHD

Translating mRNA Vaccines and Therapeutics: First Clinical Steps

Venture Partner, OrbiMed, United States

Sarah Beach Voytek

Considerations for the Nonclinical Development of Systemically-Administered Therapeutic mRNA

Principal Scientist , Novartis Institutes For Biomedical Research, Inc., United States

Clinical Development of mRNA Vaccines and Immunotherapies: Experiences and Lessons Learned

Chief Medical Officer, Curevac, Germany

Regulatory Perspective on the Product-Related (CMC) Aspects of mRNA Vaccines

Laboratory Chief, Laboratory of DNA Viruses, DVP, CBER, FDA, United States

Panel Discussion

, All Session Speakers, United States

¿Tiene una cuenta?